MedTrace Logo

Eplerenone for the Treatment of Central Serous Chorioretinopathy

NCT01990677 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2018-11-07

Study results available
· View outcomes & findings →

Summary

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

25mg Eplerenone

Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo

DRUG

Placebo

Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.

Sponsors & Collaborators

  • Mid Atlantic Retina

    collaborator OTHER

  • Wills Eye

    lead OTHER

Principal Investigators

  • Mitchell Fineman, MD · Mid Atlantic Retina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-03-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990677 on ClinicalTrials.gov